MITSUBISHI-POWER
1.9.2020 03:02:04 CEST | Business Wire | Press release
Mitsubishi Power, a major subsidiary of the Mitsubishi Heavy Industries (MHI) Group, officially changed its corporate name from Mitsubishi Hitachi Power Systems today. The rebrand marks the start of an exciting new chapter in the company’s mission to solve the foremost energy challenges of our time, including decarbonizing energy and bringing reliable power to people all over the world. With its new brand identity, which was developed after consultation with key customers, employees and partners, Mitsubishi Power moves forward in its ambition to become a leading energy solutions company with a broad spectrum of businesses in grid-level power generation, renewables, energy storage and digital technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005285/en/
Following the rebrand, Mitsubishi Power becomes a wholly owned subsidiary of MHI Group. Its enhanced position within the Group will enable it to establish greater synergies with its sister companies and expand its business by tapping new customer categories. Mitsubishi Power will capitalize on existing investments in emerging energy solutions, such as hydrogen, ammonia and solar power, to address the diverse and increasingly complex energy needs of customers around the world.
Mr. Ken Kawai, President and CEO of Mitsubishi Power, Ltd., said, “Providing people access to clean, stable, and affordable power is among global society’s most urgent mandates today. With our new identity, Mitsubishi Power is exceptionally poised to lead in solving these challenges. Building on a legacy of strong engineering and distinctive service, we will develop even more cutting-edge solutions to better serve our customers while broadening our portfolio. As an energy solutions company, we will partner more closely with governments, utilities, industry leaders and our fellow companies within the MHI Group to create a future that is good for people and the planet.”
In addition to the new name and logo, Mitsubishi Power also unveiled a new mission statement and announced that it will adopt the MHI Group tagline “Move the World Forward” (See Annex A).
Throughout its history, Mitsubishi Power has built a strong position as a trusted partner to power generation companies globally. As it enters this new phase, the company will apply its world-leading engineering prowess, drive for innovation and renowned customer service to deliver reliable energy, ultimately galvanizing the progress of nations, communities and individuals everywhere.
About Mitsubishi Power, Ltd.
Mitsubishi Power, Ltd. is a leading provider and innovator of technology and solutions for the global energy sector. Headquartered in Yokohama, Japan, it is a wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd., whose engineering and manufacturing businesses span energy, infrastructure, transport, aerospace and defense. With more than 18,000 employees across 31 countries worldwide, Mitsubishi Power designs, manufactures and maintains equipment and systems that drive decarbonization and ensure delivery of reliable power around the world. Among its solutions are a wide range of gas turbines including hydrogen-fueled gas turbines, solid-oxide fuel cells (SOFCs), and air quality control systems (AQCS). Committed to providing exemplary service and working with customers to imagine the future of energy, Mitsubishi Power is also spearheading the development of the digital power plant through its suite of AI-enabled TOMONITM solutions.
For more information, please visit https://power.mhi.com .
ANNEX A: Mitsubishi Power Corporate Identity
Brand Logo and Name
The new brand logo combines the three diamonds figurative mark of Mitsubishi with the English company name. The logo font, a roundish, modern design in a gothic typeface, was adopted to present an image of the advanced, environment-friendly power generation technologies that Mitsubishi Power seeks to offer, while at the same time expresses a corporate stance of responding flexibly to societal changes.
Mission Statement
Mitsubishi Power is creating a future that works for people and the planet by developing innovative power generation technology and solutions to enable the decarbonization of energy and deliver reliable power everywhere.
Tagline
“Move the World Forward”
ANNEX B: Mitsubishi Power Corporate Information
Representative |
Ken Kawai, President and CEO |
Global Headquarters |
3-1, Minato Mirai 3-chome, Nishi-ku, Yokohama, Kanagawa, Japan |
Regional Headquarters |
Asia Pacific: Singapore Greater China: Shanghai Europe, Middle East and Africa: London Americas: Lake Mary, Florida |
Number of Employees Globally |
18,356 (as of April 2020) |
Number of Main Group Companies |
69 companies (including 8 companies in Japan) |
Major Offerings |
Power plants:
Products, equipment and services:
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005285/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom